nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—FLT4—polycystic ovary syndrome	0.65	1	CbGaD
Pazopanib—BMPR1B—ovarian follicle—polycystic ovary syndrome	0.00864	0.0651	CbGeAlD
Pazopanib—UGT1A1—urine—polycystic ovary syndrome	0.00198	0.0149	CbGeAlD
Pazopanib—Nail disorder—Metformin—polycystic ovary syndrome	0.00152	0.0553	CcSEcCtD
Pazopanib—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00122	0.0443	CcSEcCtD
Pazopanib—ITK—endometrium—polycystic ovary syndrome	0.0012	0.00907	CbGeAlD
Pazopanib—FGFR3—embryo—polycystic ovary syndrome	0.00118	0.00889	CbGeAlD
Pazopanib—MAP3K9—adrenal gland—polycystic ovary syndrome	0.00118	0.00889	CbGeAlD
Pazopanib—SH2B3—adrenal cortex—polycystic ovary syndrome	0.00116	0.00871	CbGeAlD
Pazopanib—MAP3K9—female gonad—polycystic ovary syndrome	0.0011	0.00829	CbGeAlD
Pazopanib—TAOK1—endometrium—polycystic ovary syndrome	0.0011	0.00826	CbGeAlD
Pazopanib—MAP3K9—vagina—polycystic ovary syndrome	0.00109	0.00824	CbGeAlD
Pazopanib—ITK—adipose tissue—polycystic ovary syndrome	0.00108	0.00818	CbGeAlD
Pazopanib—SH2B3—endometrium—polycystic ovary syndrome	0.00103	0.00777	CbGeAlD
Pazopanib—TAOK1—uterus—polycystic ovary syndrome	0.00101	0.00761	CbGeAlD
Pazopanib—TAOK1—pituitary gland—polycystic ovary syndrome	0.000991	0.00747	CbGeAlD
Pazopanib—TAOK1—adipose tissue—polycystic ovary syndrome	0.000987	0.00744	CbGeAlD
Pazopanib—ITK—adrenal gland—polycystic ovary syndrome	0.000973	0.00733	CbGeAlD
Pazopanib—SH2B3—uterus—polycystic ovary syndrome	0.00095	0.00716	CbGeAlD
Pazopanib—SH2B3—pituitary gland—polycystic ovary syndrome	0.000933	0.00704	CbGeAlD
Pazopanib—SH2B3—adipose tissue—polycystic ovary syndrome	0.00093	0.00701	CbGeAlD
Pazopanib—FLT4—embryo—polycystic ovary syndrome	0.000921	0.00694	CbGeAlD
Pazopanib—ITK—vagina—polycystic ovary syndrome	0.000902	0.0068	CbGeAlD
Pazopanib—TAOK1—adrenal gland—polycystic ovary syndrome	0.000886	0.00668	CbGeAlD
Pazopanib—CYP1A2—urine—polycystic ovary syndrome	0.000876	0.00661	CbGeAlD
Pazopanib—STK36—adrenal cortex—polycystic ovary syndrome	0.000868	0.00655	CbGeAlD
Pazopanib—RIOK2—endometrium—polycystic ovary syndrome	0.000863	0.00651	CbGeAlD
Pazopanib—PI4KB—adrenal cortex—polycystic ovary syndrome	0.000855	0.00645	CbGeAlD
Pazopanib—ITK—endocrine gland—polycystic ovary syndrome	0.000844	0.00636	CbGeAlD
Pazopanib—SH2B3—adrenal gland—polycystic ovary syndrome	0.000834	0.00628	CbGeAlD
Pazopanib—TAOK1—female gonad—polycystic ovary syndrome	0.000826	0.00622	CbGeAlD
Pazopanib—AURKC—adrenal gland—polycystic ovary syndrome	0.000821	0.00619	CbGeAlD
Pazopanib—TAOK1—vagina—polycystic ovary syndrome	0.000821	0.00619	CbGeAlD
Pazopanib—FGF1—embryo—polycystic ovary syndrome	0.000818	0.00616	CbGeAlD
Pazopanib—STK16—pituitary gland—polycystic ovary syndrome	0.000794	0.00598	CbGeAlD
Pazopanib—STK16—adipose tissue—polycystic ovary syndrome	0.00079	0.00596	CbGeAlD
Pazopanib—BMPR1B—uterus—polycystic ovary syndrome	0.000788	0.00594	CbGeAlD
Pazopanib—RIOK2—pituitary gland—polycystic ovary syndrome	0.000781	0.00589	CbGeAlD
Pazopanib—RIOK2—adipose tissue—polycystic ovary syndrome	0.000778	0.00586	CbGeAlD
Pazopanib—SH2B3—female gonad—polycystic ovary syndrome	0.000777	0.00586	CbGeAlD
Pazopanib—STK36—endometrium—polycystic ovary syndrome	0.000775	0.00585	CbGeAlD
Pazopanib—SH2B3—vagina—polycystic ovary syndrome	0.000773	0.00582	CbGeAlD
Pazopanib—FGFR2—embryo—polycystic ovary syndrome	0.000772	0.00582	CbGeAlD
Pazopanib—BMPR1B—adipose tissue—polycystic ovary syndrome	0.00077	0.00581	CbGeAlD
Pazopanib—TAOK1—endocrine gland—polycystic ovary syndrome	0.000768	0.00579	CbGeAlD
Pazopanib—PI4KB—endometrium—polycystic ovary syndrome	0.000764	0.00576	CbGeAlD
Pazopanib—FLT4—adrenal cortex—polycystic ovary syndrome	0.000754	0.00569	CbGeAlD
Pazopanib—PLK4—adrenal gland—polycystic ovary syndrome	0.000751	0.00566	CbGeAlD
Pazopanib—PIP4K2C—adrenal cortex—polycystic ovary syndrome	0.00075	0.00566	CbGeAlD
Pazopanib—LIMK2—endometrium—polycystic ovary syndrome	0.00075	0.00565	CbGeAlD
Pazopanib—Lethargy—Metformin—polycystic ovary syndrome	0.00073	0.0266	CcSEcCtD
Pazopanib—FLT1—embryo—polycystic ovary syndrome	0.000716	0.0054	CbGeAlD
Pazopanib—AURKC—endocrine gland—polycystic ovary syndrome	0.000712	0.00537	CbGeAlD
Pazopanib—STK16—adrenal gland—polycystic ovary syndrome	0.000709	0.00534	CbGeAlD
Pazopanib—PI4KB—uterus—polycystic ovary syndrome	0.000704	0.0053	CbGeAlD
Pazopanib—STK36—pituitary gland—polycystic ovary syndrome	0.000702	0.00529	CbGeAlD
Pazopanib—STK36—adipose tissue—polycystic ovary syndrome	0.000699	0.00527	CbGeAlD
Pazopanib—RIOK2—adrenal gland—polycystic ovary syndrome	0.000698	0.00526	CbGeAlD
Pazopanib—FGFR3—adrenal gland—polycystic ovary syndrome	0.000698	0.00526	CbGeAlD
Pazopanib—PI4KB—pituitary gland—polycystic ovary syndrome	0.000691	0.00521	CbGeAlD
Pazopanib—BMPR1B—adrenal gland—polycystic ovary syndrome	0.000691	0.00521	CbGeAlD
Pazopanib—LIMK2—uterus—polycystic ovary syndrome	0.000691	0.00521	CbGeAlD
Pazopanib—PI4KB—adipose tissue—polycystic ovary syndrome	0.000688	0.00519	CbGeAlD
Pazopanib—LIMK2—pituitary gland—polycystic ovary syndrome	0.000678	0.00511	CbGeAlD
Pazopanib—LIMK2—adipose tissue—polycystic ovary syndrome	0.000676	0.00509	CbGeAlD
Pazopanib—PDGFRA—embryo—polycystic ovary syndrome	0.000671	0.00506	CbGeAlD
Pazopanib—PIP4K2C—endometrium—polycystic ovary syndrome	0.00067	0.00505	CbGeAlD
Pazopanib—Dehydration—Metformin—polycystic ovary syndrome	0.000666	0.0242	CcSEcCtD
Pazopanib—STK16—female gonad—polycystic ovary syndrome	0.000661	0.00498	CbGeAlD
Pazopanib—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000661	0.024	CcSEcCtD
Pazopanib—STK16—vagina—polycystic ovary syndrome	0.000657	0.00495	CbGeAlD
Pazopanib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000654	0.0238	CcSEcCtD
Pazopanib—PLK4—endocrine gland—polycystic ovary syndrome	0.000651	0.00491	CbGeAlD
Pazopanib—RIOK2—female gonad—polycystic ovary syndrome	0.000651	0.00491	CbGeAlD
Pazopanib—RIOK2—vagina—polycystic ovary syndrome	0.000647	0.00488	CbGeAlD
Pazopanib—Breast disorder—Metformin—polycystic ovary syndrome	0.000647	0.0235	CcSEcCtD
Pazopanib—BMPR1B—female gonad—polycystic ovary syndrome	0.000644	0.00486	CbGeAlD
Pazopanib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00064	0.0233	CcSEcCtD
Pazopanib—CYP3A4—urine—polycystic ovary syndrome	0.000634	0.00478	CbGeAlD
Pazopanib—STK36—adrenal gland—polycystic ovary syndrome	0.000627	0.00473	CbGeAlD
Pazopanib—CYP2D6—urine—polycystic ovary syndrome	0.000624	0.00471	CbGeAlD
Pazopanib—Abdominal distension—Metformin—polycystic ovary syndrome	0.000623	0.0226	CcSEcCtD
Pazopanib—PI4KB—adrenal gland—polycystic ovary syndrome	0.000617	0.00465	CbGeAlD
Pazopanib—STK16—endocrine gland—polycystic ovary syndrome	0.000615	0.00463	CbGeAlD
Pazopanib—FGFR1—uterus—polycystic ovary syndrome	0.000612	0.00462	CbGeAlD
Pazopanib—LYN—endocrine gland—polycystic ovary syndrome	0.000608	0.00459	CbGeAlD
Pazopanib—FLT4—adipose tissue—polycystic ovary syndrome	0.000607	0.00458	CbGeAlD
Pazopanib—Pancreatitis—Metformin—polycystic ovary syndrome	0.000606	0.0221	CcSEcCtD
Pazopanib—PIP4K2C—pituitary gland—polycystic ovary syndrome	0.000606	0.00457	CbGeAlD
Pazopanib—LIMK2—adrenal gland—polycystic ovary syndrome	0.000606	0.00457	CbGeAlD
Pazopanib—FGFR3—endocrine gland—polycystic ovary syndrome	0.000605	0.00456	CbGeAlD
Pazopanib—KDR—embryo—polycystic ovary syndrome	0.000605	0.00456	CbGeAlD
Pazopanib—PIP4K2C—adipose tissue—polycystic ovary syndrome	0.000604	0.00455	CbGeAlD
Pazopanib—FGFR1—pituitary gland—polycystic ovary syndrome	0.000601	0.00453	CbGeAlD
Pazopanib—BMPR1B—endocrine gland—polycystic ovary syndrome	0.000599	0.00452	CbGeAlD
Pazopanib—FGFR1—adipose tissue—polycystic ovary syndrome	0.000599	0.00451	CbGeAlD
Pazopanib—CSF1R—embryo—polycystic ovary syndrome	0.000591	0.00445	CbGeAlD
Pazopanib—FLT1—adrenal cortex—polycystic ovary syndrome	0.000587	0.00442	CbGeAlD
Pazopanib—MAP3K2—uterus—polycystic ovary syndrome	0.000585	0.00441	CbGeAlD
Pazopanib—STK36—female gonad—polycystic ovary syndrome	0.000585	0.00441	CbGeAlD
Pazopanib—STK36—vagina—polycystic ovary syndrome	0.000581	0.00438	CbGeAlD
Pazopanib—Neutropenia—Metformin—polycystic ovary syndrome	0.000578	0.021	CcSEcCtD
Pazopanib—PI4KB—female gonad—polycystic ovary syndrome	0.000576	0.00434	CbGeAlD
Pazopanib—MAP3K2—adipose tissue—polycystic ovary syndrome	0.000572	0.00431	CbGeAlD
Pazopanib—PI4KB—vagina—polycystic ovary syndrome	0.000572	0.00431	CbGeAlD
Pazopanib—LIMK2—female gonad—polycystic ovary syndrome	0.000565	0.00426	CbGeAlD
Pazopanib—LIMK2—vagina—polycystic ovary syndrome	0.000562	0.00423	CbGeAlD
Pazopanib—TAOK3—adrenal cortex—polycystic ovary syndrome	0.000553	0.00417	CbGeAlD
Pazopanib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000552	0.0201	CcSEcCtD
Pazopanib—Infestation—Metformin—polycystic ovary syndrome	0.000552	0.0201	CcSEcCtD
Pazopanib—LCK—uterus—polycystic ovary syndrome	0.000548	0.00413	CbGeAlD
Pazopanib—FLT4—adrenal gland—polycystic ovary syndrome	0.000545	0.00411	CbGeAlD
Pazopanib—STK36—endocrine gland—polycystic ovary syndrome	0.000544	0.0041	CbGeAlD
Pazopanib—PIP4K2C—adrenal gland—polycystic ovary syndrome	0.000542	0.00408	CbGeAlD
Pazopanib—FGF1—pituitary gland—polycystic ovary syndrome	0.000541	0.00408	CbGeAlD
Pazopanib—FGF1—adipose tissue—polycystic ovary syndrome	0.000539	0.00407	CbGeAlD
Pazopanib—FGFR1—adrenal gland—polycystic ovary syndrome	0.000537	0.00405	CbGeAlD
Pazopanib—KIT—embryo—polycystic ovary syndrome	0.000536	0.00404	CbGeAlD
Pazopanib—LCK—adipose tissue—polycystic ovary syndrome	0.000536	0.00404	CbGeAlD
Pazopanib—PI4KB—endocrine gland—polycystic ovary syndrome	0.000535	0.00404	CbGeAlD
Pazopanib—LIMK2—endocrine gland—polycystic ovary syndrome	0.000526	0.00396	CbGeAlD
Pazopanib—FLT1—endometrium—polycystic ovary syndrome	0.000524	0.00395	CbGeAlD
Pazopanib—PDGFRB—embryo—polycystic ovary syndrome	0.000524	0.00395	CbGeAlD
Pazopanib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000522	0.019	CcSEcCtD
Pazopanib—FGFR2—uterus—polycystic ovary syndrome	0.000521	0.00393	CbGeAlD
Pazopanib—EPHB6—endometrium—polycystic ovary syndrome	0.000518	0.0039	CbGeAlD
Pazopanib—MAP3K2—adrenal gland—polycystic ovary syndrome	0.000513	0.00387	CbGeAlD
Pazopanib—FGFR2—adipose tissue—polycystic ovary syndrome	0.000509	0.00384	CbGeAlD
Pazopanib—FLT4—female gonad—polycystic ovary syndrome	0.000508	0.00383	CbGeAlD
Pazopanib—PIP4K2C—female gonad—polycystic ovary syndrome	0.000505	0.00381	CbGeAlD
Pazopanib—Bradycardia—Metformin—polycystic ovary syndrome	0.000504	0.0183	CcSEcCtD
Pazopanib—PIP4K2C—vagina—polycystic ovary syndrome	0.000502	0.00378	CbGeAlD
Pazopanib—FGFR1—female gonad—polycystic ovary syndrome	0.000501	0.00378	CbGeAlD
Pazopanib—FGFR1—vagina—polycystic ovary syndrome	0.000498	0.00375	CbGeAlD
Pazopanib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000496	0.00374	CbGeAlD
Pazopanib—KDR—adrenal cortex—polycystic ovary syndrome	0.000496	0.00374	CbGeAlD
Pazopanib—TAOK3—endometrium—polycystic ovary syndrome	0.000494	0.00372	CbGeAlD
Pazopanib—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000493	0.0179	CcSEcCtD
Pazopanib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000488	0.0177	CcSEcCtD
Pazopanib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000487	0.0177	CcSEcCtD
Pazopanib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.000484	0.00365	CbGeAlD
Pazopanib—FGF1—adrenal gland—polycystic ovary syndrome	0.000484	0.00365	CbGeAlD
Pazopanib—FLT1—uterus—polycystic ovary syndrome	0.000483	0.00364	CbGeAlD
Pazopanib—LCK—adrenal gland—polycystic ovary syndrome	0.000481	0.00362	CbGeAlD
Pazopanib—MAP3K2—female gonad—polycystic ovary syndrome	0.000479	0.00361	CbGeAlD
Pazopanib—FLT1—pituitary gland—polycystic ovary syndrome	0.000474	0.00357	CbGeAlD
Pazopanib—FLT4—endocrine gland—polycystic ovary syndrome	0.000472	0.00356	CbGeAlD
Pazopanib—FLT1—adipose tissue—polycystic ovary syndrome	0.000472	0.00356	CbGeAlD
Pazopanib—PIP4K2C—endocrine gland—polycystic ovary syndrome	0.00047	0.00354	CbGeAlD
Pazopanib—EPHB6—pituitary gland—polycystic ovary syndrome	0.000469	0.00353	CbGeAlD
Pazopanib—EPHB6—adipose tissue—polycystic ovary syndrome	0.000467	0.00352	CbGeAlD
Pazopanib—Eye disorder—Metformin—polycystic ovary syndrome	0.000463	0.0168	CcSEcCtD
Pazopanib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00046	0.0167	CcSEcCtD
Pazopanib—Flushing—Metformin—polycystic ovary syndrome	0.00046	0.0167	CcSEcCtD
Pazopanib—STK10—uterus—polycystic ovary syndrome	0.000457	0.00344	CbGeAlD
Pazopanib—FGFR2—adrenal gland—polycystic ovary syndrome	0.000457	0.00344	CbGeAlD
Pazopanib—TAOK3—uterus—polycystic ovary syndrome	0.000455	0.00343	CbGeAlD
Pazopanib—PDGFRA—uterus—polycystic ovary syndrome	0.000452	0.00341	CbGeAlD
Pazopanib—FGF1—female gonad—polycystic ovary syndrome	0.000451	0.0034	CbGeAlD
Pazopanib—Angiopathy—Metformin—polycystic ovary syndrome	0.000449	0.0163	CcSEcCtD
Pazopanib—LCK—female gonad—polycystic ovary syndrome	0.000448	0.00338	CbGeAlD
Pazopanib—TAOK3—pituitary gland—polycystic ovary syndrome	0.000447	0.00337	CbGeAlD
Pazopanib—STK10—adipose tissue—polycystic ovary syndrome	0.000447	0.00337	CbGeAlD
Pazopanib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000446	0.0162	CcSEcCtD
Pazopanib—LCK—vagina—polycystic ovary syndrome	0.000446	0.00336	CbGeAlD
Pazopanib—MAP3K2—endocrine gland—polycystic ovary syndrome	0.000445	0.00336	CbGeAlD
Pazopanib—TAOK3—adipose tissue—polycystic ovary syndrome	0.000445	0.00336	CbGeAlD
Pazopanib—Chills—Metformin—polycystic ovary syndrome	0.000444	0.0162	CcSEcCtD
Pazopanib—MAP2K5—endometrium—polycystic ovary syndrome	0.000443	0.00334	CbGeAlD
Pazopanib—KDR—endometrium—polycystic ovary syndrome	0.000443	0.00334	CbGeAlD
Pazopanib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.000442	0.00333	CbGeAlD
Pazopanib—CSF1R—endometrium—polycystic ovary syndrome	0.000432	0.00326	CbGeAlD
Pazopanib—Erythema—Metformin—polycystic ovary syndrome	0.000431	0.0157	CcSEcCtD
Pazopanib—Malnutrition—Metformin—polycystic ovary syndrome	0.000431	0.0157	CcSEcCtD
Pazopanib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000429	0.00324	CbGeAlD
Pazopanib—FGFR2—female gonad—polycystic ovary syndrome	0.000426	0.00321	CbGeAlD
Pazopanib—Flatulence—Metformin—polycystic ovary syndrome	0.000425	0.0154	CcSEcCtD
Pazopanib—FLT1—adrenal gland—polycystic ovary syndrome	0.000423	0.00319	CbGeAlD
Pazopanib—Dysgeusia—Metformin—polycystic ovary syndrome	0.000422	0.0153	CcSEcCtD
Pazopanib—FGF1—endocrine gland—polycystic ovary syndrome	0.000419	0.00316	CbGeAlD
Pazopanib—EPHB6—adrenal gland—polycystic ovary syndrome	0.000419	0.00316	CbGeAlD
Pazopanib—Muscle spasms—Metformin—polycystic ovary syndrome	0.000414	0.0151	CcSEcCtD
Pazopanib—KDR—uterus—polycystic ovary syndrome	0.000408	0.00308	CbGeAlD
Pazopanib—Vision blurred—Metformin—polycystic ovary syndrome	0.000406	0.0148	CcSEcCtD
Pazopanib—STK10—adrenal gland—polycystic ovary syndrome	0.000401	0.00302	CbGeAlD
Pazopanib—KDR—pituitary gland—polycystic ovary syndrome	0.000401	0.00302	CbGeAlD
Pazopanib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000401	0.00302	CbGeAlD
Pazopanib—TAOK3—adrenal gland—polycystic ovary syndrome	0.000399	0.00301	CbGeAlD
Pazopanib—KDR—adipose tissue—polycystic ovary syndrome	0.000399	0.00301	CbGeAlD
Pazopanib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.000399	0.00301	CbGeAlD
Pazopanib—CSF1R—uterus—polycystic ovary syndrome	0.000398	0.003	CbGeAlD
Pazopanib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.000397	0.00299	CbGeAlD
Pazopanib—FGFR2—endocrine gland—polycystic ovary syndrome	0.000396	0.00299	CbGeAlD
Pazopanib—FLT1—female gonad—polycystic ovary syndrome	0.000395	0.00298	CbGeAlD
Pazopanib—FLT1—vagina—polycystic ovary syndrome	0.000392	0.00296	CbGeAlD
Pazopanib—KIT—endometrium—polycystic ovary syndrome	0.000392	0.00296	CbGeAlD
Pazopanib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000391	0.00295	CbGeAlD
Pazopanib—EPHB6—female gonad—polycystic ovary syndrome	0.00039	0.00294	CbGeAlD
Pazopanib—CSF1R—adipose tissue—polycystic ovary syndrome	0.000389	0.00294	CbGeAlD
Pazopanib—EPHB6—vagina—polycystic ovary syndrome	0.000388	0.00292	CbGeAlD
Pazopanib—Syncope—Metformin—polycystic ovary syndrome	0.000387	0.0141	CcSEcCtD
Pazopanib—PDGFRB—endometrium—polycystic ovary syndrome	0.000383	0.00289	CbGeAlD
Pazopanib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000379	0.0138	CcSEcCtD
Pazopanib—STK10—female gonad—polycystic ovary syndrome	0.000374	0.00282	CbGeAlD
Pazopanib—TAOK3—female gonad—polycystic ovary syndrome	0.000372	0.00281	CbGeAlD
Pazopanib—Hypertension—Metformin—polycystic ovary syndrome	0.000372	0.0135	CcSEcCtD
Pazopanib—STK10—vagina—polycystic ovary syndrome	0.000371	0.0028	CbGeAlD
Pazopanib—TAOK3—vagina—polycystic ovary syndrome	0.00037	0.00279	CbGeAlD
Pazopanib—PDGFRA—female gonad—polycystic ovary syndrome	0.00037	0.00279	CbGeAlD
Pazopanib—PDGFRA—vagina—polycystic ovary syndrome	0.000368	0.00277	CbGeAlD
Pazopanib—FLT1—endocrine gland—polycystic ovary syndrome	0.000367	0.00277	CbGeAlD
Pazopanib—Chest pain—Metformin—polycystic ovary syndrome	0.000367	0.0133	CcSEcCtD
Pazopanib—Myalgia—Metformin—polycystic ovary syndrome	0.000367	0.0133	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000364	0.0133	CcSEcCtD
Pazopanib—KIT—uterus—polycystic ovary syndrome	0.000362	0.00273	CbGeAlD
Pazopanib—KDR—adrenal gland—polycystic ovary syndrome	0.000358	0.0027	CbGeAlD
Pazopanib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.000358	0.0027	CbGeAlD
Pazopanib—KIT—pituitary gland—polycystic ovary syndrome	0.000355	0.00268	CbGeAlD
Pazopanib—KIT—adipose tissue—polycystic ovary syndrome	0.000354	0.00267	CbGeAlD
Pazopanib—PDGFRB—uterus—polycystic ovary syndrome	0.000353	0.00266	CbGeAlD
Pazopanib—Oedema—Metformin—polycystic ovary syndrome	0.000352	0.0128	CcSEcCtD
Pazopanib—Infection—Metformin—polycystic ovary syndrome	0.000349	0.0127	CcSEcCtD
Pazopanib—CSF1R—adrenal gland—polycystic ovary syndrome	0.000349	0.00263	CbGeAlD
Pazopanib—STK10—endocrine gland—polycystic ovary syndrome	0.000348	0.00262	CbGeAlD
Pazopanib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000347	0.00261	CbGeAlD
Pazopanib—TAOK3—endocrine gland—polycystic ovary syndrome	0.000346	0.00261	CbGeAlD
Pazopanib—Shock—Metformin—polycystic ovary syndrome	0.000346	0.0126	CcSEcCtD
Pazopanib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000345	0.0026	CbGeAlD
Pazopanib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000345	0.0125	CcSEcCtD
Pazopanib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000344	0.0125	CcSEcCtD
Pazopanib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.000344	0.00259	CbGeAlD
Pazopanib—Skin disorder—Metformin—polycystic ovary syndrome	0.000342	0.0124	CcSEcCtD
Pazopanib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00034	0.0124	CcSEcCtD
Pazopanib—Anorexia—Metformin—polycystic ovary syndrome	0.000335	0.0122	CcSEcCtD
Pazopanib—KDR—female gonad—polycystic ovary syndrome	0.000334	0.00252	CbGeAlD
Pazopanib—MAP2K5—female gonad—polycystic ovary syndrome	0.000334	0.00252	CbGeAlD
Pazopanib—KDR—vagina—polycystic ovary syndrome	0.000332	0.0025	CbGeAlD
Pazopanib—MAP2K5—vagina—polycystic ovary syndrome	0.000332	0.0025	CbGeAlD
Pazopanib—UGT1A1—endocrine gland—polycystic ovary syndrome	0.000328	0.00247	CbGeAlD
Pazopanib—CSF1R—female gonad—polycystic ovary syndrome	0.000326	0.00246	CbGeAlD
Pazopanib—CSF1R—vagina—polycystic ovary syndrome	0.000324	0.00244	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00032	0.0117	CcSEcCtD
Pazopanib—KIT—adrenal gland—polycystic ovary syndrome	0.000317	0.00239	CbGeAlD
Pazopanib—Paraesthesia—Metformin—polycystic ovary syndrome	0.000316	0.0115	CcSEcCtD
Pazopanib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000314	0.0114	CcSEcCtD
Pazopanib—Somnolence—Metformin—polycystic ovary syndrome	0.000313	0.0114	CcSEcCtD
Pazopanib—KDR—endocrine gland—polycystic ovary syndrome	0.00031	0.00234	CbGeAlD
Pazopanib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.00031	0.00234	CbGeAlD
Pazopanib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.00031	0.00234	CbGeAlD
Pazopanib—Dyspepsia—Metformin—polycystic ovary syndrome	0.00031	0.0113	CcSEcCtD
Pazopanib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000306	0.0111	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000304	0.011	CcSEcCtD
Pazopanib—Fatigue—Metformin—polycystic ovary syndrome	0.000303	0.011	CcSEcCtD
Pazopanib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000303	0.00228	CbGeAlD
Pazopanib—KIT—female gonad—polycystic ovary syndrome	0.000296	0.00223	CbGeAlD
Pazopanib—KIT—vagina—polycystic ovary syndrome	0.000294	0.00222	CbGeAlD
Pazopanib—PDGFRB—female gonad—polycystic ovary syndrome	0.000289	0.00218	CbGeAlD
Pazopanib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000288	0.0105	CcSEcCtD
Pazopanib—PDGFRB—vagina—polycystic ovary syndrome	0.000287	0.00216	CbGeAlD
Pazopanib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000278	0.0101	CcSEcCtD
Pazopanib—KIT—endocrine gland—polycystic ovary syndrome	0.000275	0.00207	CbGeAlD
Pazopanib—SLCO1B1—endocrine gland—polycystic ovary syndrome	0.000273	0.00206	CbGeAlD
Pazopanib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000269	0.00203	CbGeAlD
Pazopanib—Asthenia—Metformin—polycystic ovary syndrome	0.000252	0.00918	CcSEcCtD
Pazopanib—Pruritus—Metformin—polycystic ovary syndrome	0.000249	0.00905	CcSEcCtD
Pazopanib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000241	0.00182	CbGeAlD
Pazopanib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000241	0.00875	CcSEcCtD
Pazopanib—Dizziness—Metformin—polycystic ovary syndrome	0.000233	0.00846	CcSEcCtD
Pazopanib—Vomiting—Metformin—polycystic ovary syndrome	0.000224	0.00813	CcSEcCtD
Pazopanib—Rash—Metformin—polycystic ovary syndrome	0.000222	0.00807	CcSEcCtD
Pazopanib—Dermatitis—Metformin—polycystic ovary syndrome	0.000222	0.00806	CcSEcCtD
Pazopanib—CYP2C8—endometrium—polycystic ovary syndrome	0.000222	0.00167	CbGeAlD
Pazopanib—Headache—Metformin—polycystic ovary syndrome	0.00022	0.00801	CcSEcCtD
Pazopanib—ABCG2—endometrium—polycystic ovary syndrome	0.000215	0.00162	CbGeAlD
Pazopanib—Nausea—Metformin—polycystic ovary syndrome	0.000209	0.0076	CcSEcCtD
Pazopanib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.0002	0.00151	CbGeAlD
Pazopanib—ABCG2—uterus—polycystic ovary syndrome	0.000199	0.0015	CbGeAlD
Pazopanib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000195	0.00147	CbGeAlD
Pazopanib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000194	0.00146	CbGeAlD
Pazopanib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000174	0.00131	CbGeAlD
Pazopanib—CYP2C8—vagina—polycystic ovary syndrome	0.000166	0.00125	CbGeAlD
Pazopanib—ABCG2—female gonad—polycystic ovary syndrome	0.000162	0.00122	CbGeAlD
Pazopanib—ABCG2—vagina—polycystic ovary syndrome	0.000161	0.00122	CbGeAlD
Pazopanib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000155	0.00117	CbGeAlD
Pazopanib—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000145	0.0011	CbGeAlD
Pazopanib—ABCB1—embryo—polycystic ovary syndrome	0.000145	0.00109	CbGeAlD
Pazopanib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000119	0.000897	CbGeAlD
Pazopanib—CYP2D6—female gonad—polycystic ovary syndrome	0.000111	0.000839	CbGeAlD
Pazopanib—ABCB1—endometrium—polycystic ovary syndrome	0.000106	0.000801	CbGeAlD
Pazopanib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000105	0.000793	CbGeAlD
Pazopanib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000104	0.00078	CbGeAlD
Pazopanib—ABCB1—uterus—polycystic ovary syndrome	9.79e-05	0.000738	CbGeAlD
Pazopanib—ABCB1—pituitary gland—polycystic ovary syndrome	9.61e-05	0.000725	CbGeAlD
Pazopanib—ABCB1—adipose tissue—polycystic ovary syndrome	9.57e-05	0.000722	CbGeAlD
Pazopanib—ABCB1—adrenal gland—polycystic ovary syndrome	8.59e-05	0.000647	CbGeAlD
Pazopanib—ABCB1—female gonad—polycystic ovary syndrome	8.01e-05	0.000604	CbGeAlD
Pazopanib—ABCB1—vagina—polycystic ovary syndrome	7.96e-05	0.0006	CbGeAlD
Pazopanib—ABCB1—endocrine gland—polycystic ovary syndrome	7.45e-05	0.000561	CbGeAlD
Pazopanib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	3.52e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—LEP—polycystic ovary syndrome	3.5e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRG1—polycystic ovary syndrome	3.5e-06	1.84e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	3.5e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.5e-06	1.84e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.5e-06	1.84e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.49e-06	1.84e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.48e-06	1.83e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	3.48e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—IL6—polycystic ovary syndrome	3.47e-06	1.83e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	3.47e-06	1.82e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT2—polycystic ovary syndrome	3.46e-06	1.82e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—MTHFR—polycystic ovary syndrome	3.45e-06	1.82e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NGFR—polycystic ovary syndrome	3.45e-06	1.81e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—LEP—polycystic ovary syndrome	3.44e-06	1.81e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IRS2—polycystic ovary syndrome	3.44e-06	1.81e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRG1—polycystic ovary syndrome	3.43e-06	1.8e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	3.42e-06	1.8e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PRL—polycystic ovary syndrome	3.42e-06	1.8e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—IL6—polycystic ovary syndrome	3.41e-06	1.79e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	3.41e-06	1.79e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CYP1A1—polycystic ovary syndrome	3.4e-06	1.79e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—IL6—polycystic ovary syndrome	3.34e-06	1.76e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.34e-06	1.76e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	3.33e-06	1.75e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IRS2—polycystic ovary syndrome	3.33e-06	1.75e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.32e-06	1.75e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	3.32e-06	1.74e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	3.31e-06	1.74e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.31e-06	1.74e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	3.29e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—SERPINE1—polycystic ovary syndrome	3.29e-06	1.73e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—BCL2—polycystic ovary syndrome	3.27e-06	1.72e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.27e-06	1.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—LEP—polycystic ovary syndrome	3.27e-06	1.72e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	3.26e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—LEP—polycystic ovary syndrome	3.26e-06	1.71e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	3.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IRS1—polycystic ovary syndrome	3.25e-06	1.71e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.24e-06	1.7e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—IL6—polycystic ovary syndrome	3.24e-06	1.7e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	3.24e-06	1.7e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—IL6—polycystic ovary syndrome	3.23e-06	1.7e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—IL6—polycystic ovary syndrome	3.23e-06	1.7e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.21e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—BCL2—polycystic ovary syndrome	3.21e-06	1.69e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—MTHFR—polycystic ovary syndrome	3.17e-06	1.67e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	3.14e-06	1.65e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	3.13e-06	1.65e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.13e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	3.11e-06	1.63e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	3.09e-06	1.63e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	3.07e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	3.06e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	3.05e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	3.05e-06	1.6e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	3.02e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—POMC—polycystic ovary syndrome	3.01e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT2—polycystic ovary syndrome	3.01e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	3e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IRS1—polycystic ovary syndrome	3e-06	1.58e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	3e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—INS—polycystic ovary syndrome	2.99e-06	1.57e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	2.97e-06	1.56e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	2.96e-06	1.56e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	2.95e-06	1.55e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.95e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL6—polycystic ovary syndrome	2.94e-06	1.55e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	2.94e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	2.94e-06	1.54e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	2.93e-06	1.54e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	2.93e-06	1.54e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.91e-06	1.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	2.91e-06	1.53e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	2.91e-06	1.53e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	2.9e-06	1.53e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	2.9e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.9e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.89e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	2.87e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—INS—polycystic ovary syndrome	2.87e-06	1.51e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	2.87e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.86e-06	1.51e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	2.85e-06	1.5e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	2.85e-06	1.5e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	2.84e-06	1.5e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	2.84e-06	1.49e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	2.81e-06	1.48e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	2.81e-06	1.48e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—POMC—polycystic ovary syndrome	2.81e-06	1.48e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	2.8e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	2.8e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—INS—polycystic ovary syndrome	2.79e-06	1.47e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	2.78e-06	1.46e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT2—polycystic ovary syndrome	2.78e-06	1.46e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	2.76e-06	1.45e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.75e-06	1.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.75e-06	1.45e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—INS—polycystic ovary syndrome	2.75e-06	1.45e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	2.73e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—IL6—polycystic ovary syndrome	2.72e-06	1.43e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	2.71e-06	1.42e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	2.7e-06	1.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.7e-06	1.42e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.7e-06	1.42e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.7e-06	1.42e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	2.69e-06	1.42e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	2.69e-06	1.41e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	2.66e-06	1.4e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	2.65e-06	1.39e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—SERPINE1—polycystic ovary syndrome	2.64e-06	1.39e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.63e-06	1.38e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—BCL2—polycystic ovary syndrome	2.63e-06	1.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	2.62e-06	1.38e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	2.58e-06	1.36e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	2.57e-06	1.35e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PPARG—polycystic ovary syndrome	2.57e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	2.56e-06	1.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.56e-06	1.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.56e-06	1.34e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	2.55e-06	1.34e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—POMC—polycystic ovary syndrome	2.53e-06	1.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	2.52e-06	1.33e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—INS—polycystic ovary syndrome	2.52e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	2.51e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.51e-06	1.32e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	2.51e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	2.5e-06	1.32e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL6—polycystic ovary syndrome	2.49e-06	1.31e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	2.47e-06	1.3e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.46e-06	1.29e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	2.45e-06	1.29e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL6—polycystic ovary syndrome	2.44e-06	1.29e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	2.43e-06	1.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	2.42e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	2.42e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	2.41e-06	1.27e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	2.41e-06	1.27e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.4e-06	1.26e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	2.38e-06	1.25e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	2.37e-06	1.25e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	2.37e-06	1.25e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	2.36e-06	1.24e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	2.34e-06	1.23e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	2.33e-06	1.23e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—INS—polycystic ovary syndrome	2.33e-06	1.23e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	2.32e-06	1.22e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TH—polycystic ovary syndrome	2.31e-06	1.21e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.3e-06	1.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.3e-06	1.21e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.29e-06	1.2e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	2.29e-06	1.2e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.29e-06	1.2e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.27e-06	1.19e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—IL6—polycystic ovary syndrome	2.26e-06	1.19e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.25e-06	1.19e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.24e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.24e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	2.17e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.17e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	2.16e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	2.16e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	2.13e-06	1.12e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	2.11e-06	1.11e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	2.11e-06	1.11e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	2.1e-06	1.11e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	2.06e-06	1.08e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	2.02e-06	1.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—polycystic ovary syndrome	2.02e-06	1.06e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	2.01e-06	1.06e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.99e-06	1.05e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.99e-06	1.05e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—polycystic ovary syndrome	1.99e-06	1.05e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	1.95e-06	1.03e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	1.95e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	1.94e-06	1.02e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.93e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—polycystic ovary syndrome	1.9e-06	1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.89e-06	9.95e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—polycystic ovary syndrome	1.89e-06	9.92e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.88e-06	9.9e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	1.88e-06	9.89e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—polycystic ovary syndrome	1.87e-06	9.83e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.86e-06	9.79e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.86e-06	9.77e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.85e-06	9.72e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TH—polycystic ovary syndrome	1.84e-06	9.68e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—polycystic ovary syndrome	1.83e-06	9.65e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	1.82e-06	9.57e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.79e-06	9.43e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	1.79e-06	9.42e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.79e-06	9.41e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	1.77e-06	9.33e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.77e-06	9.29e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.76e-06	9.27e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.76e-06	9.25e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—polycystic ovary syndrome	1.74e-06	9.16e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—polycystic ovary syndrome	1.74e-06	9.13e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	8.94e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.7e-06	8.94e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	1.69e-06	8.91e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	1.69e-06	8.89e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	1.68e-06	8.85e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.67e-06	8.77e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—polycystic ovary syndrome	1.66e-06	8.73e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—polycystic ovary syndrome	1.66e-06	8.71e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.64e-06	8.64e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	1.6e-06	8.43e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.58e-06	8.34e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.58e-06	8.33e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—polycystic ovary syndrome	1.58e-06	8.31e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—polycystic ovary syndrome	1.56e-06	8.23e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.55e-06	8.16e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	1.5e-06	7.9e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	1.49e-06	7.85e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	1.47e-06	7.76e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	1.45e-06	7.65e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	1.45e-06	7.61e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	1.43e-06	7.53e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.42e-06	7.47e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.38e-06	7.27e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—polycystic ovary syndrome	1.36e-06	7.15e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.36e-06	7.14e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—polycystic ovary syndrome	1.31e-06	6.88e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.3e-06	6.83e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.28e-06	6.76e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	1.28e-06	6.76e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.27e-06	6.69e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.27e-06	6.67e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.27e-06	6.65e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.26e-06	6.63e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—polycystic ovary syndrome	1.26e-06	6.6e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—polycystic ovary syndrome	1.22e-06	6.41e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	1.22e-06	6.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.21e-06	6.37e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.19e-06	6.28e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.19e-06	6.25e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.16e-06	6.1e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.1e-06	5.81e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	1.1e-06	5.76e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	1.07e-06	5.64e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.05e-06	5.51e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.03e-06	5.4e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.01e-06	5.32e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.01e-06	5.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	9.76e-07	5.14e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	8.79e-07	4.62e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	7.92e-07	4.16e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	7.81e-07	4.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	7.76e-07	4.08e-06	CbGpPWpGaD
